miRNAs have extensive involvement in embryonic cardiomyocyte differentiation and they play essential roles during mammalian heart development.
Many miRNAs have been reported to be altered in cardiovascular disease; both cellular and extracellular levels. Multiple miRNAs have been specifically implicated in the progression of heart failure and have emerged as attractive therapeutic targets for cardiovascular diseases.
There is clinical potential for miRNA as therapeutics for cardiovascular disease
Many miRNAs have been reported to be altered in cardiovascular disease; both cellular and extracellular levels. Understanding exactly when and how miRNA expression is influencing the development of normal cells into diseased cells will undoubtedly help lead to improved diagnosis and possibly treatment for cardiovascular diseases.
Expression profiling results have shown that miRNAs are involved in cardiac hypertrophy formation and thus might be a new therapeutic target for cardiovascular diseases involving cardiac hypertrophy such as hypertension, ischemic heart disease, valvular diseases, and endocrine disorders.
Indeed, researchers have demonstrated that inhibition of specific miRNAs can spare cardiomyocytes from death during myocardial infarction.
Read more about how LC Sciences is helping clinicians and researchers to:
Cardiovascular Research Services
LC Sciences offers a range of services applicable to clinical cardiovascular research.
Contact us to find out more.